These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 34257614

  • 1. Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response.
    Xing AY, Wang B, Li YH, Chen X, Wang YW, Liu HT, Gao P.
    Pathol Oncol Res; 2021; 27():1609753. PubMed ID: 34257614
    [Abstract] [Full Text] [Related]

  • 2. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
    Iwase T, Harano K, Masuda H, Kida K, Hess KR, Wang Y, Dirix L, Van Laere SJ, Lucci A, Krishnamurthy S, Woodward WA, Layman RM, Bertucci F, Ueno NT.
    BMC Cancer; 2020 May 18; 20(1):430. PubMed ID: 32423453
    [Abstract] [Full Text] [Related]

  • 3. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer.
    McDermott AM, Miller N, Wall D, Martyn LM, Ball G, Sweeney KJ, Kerin MJ.
    PLoS One; 2014 May 18; 9(1):e87032. PubMed ID: 24498016
    [Abstract] [Full Text] [Related]

  • 4. A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
    Risi E, Grilli A, Migliaccio I, Biagioni C, McCartney A, Guarducci C, Bonechi M, Benelli M, Vitale S, Biganzoli L, Bicciato S, Di Leo A, Malorni L.
    Breast Cancer Res Treat; 2018 Jul 18; 170(2):329-341. PubMed ID: 29564743
    [Abstract] [Full Text] [Related]

  • 5. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Iwamoto T, Kelly C, Mizoo T, Nogami T, Motoki T, Shien T, Taira N, Hayashi N, Niikura N, Fujiwara T, Doihara H, Matsuoka J.
    Clin Breast Cancer; 2016 Apr 18; 16(2):95-100.e1. PubMed ID: 26631838
    [Abstract] [Full Text] [Related]

  • 6. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
    Raychaudhuri M, Bronger H, Buchner T, Kiechle M, Weichert W, Avril S.
    Breast Cancer Res Treat; 2017 Apr 18; 162(3):511-521. PubMed ID: 28181130
    [Abstract] [Full Text] [Related]

  • 7. miRNA expression patterns in chemoresistant breast cancer tissues.
    Lv J, Xia K, Xu P, Sun E, Ma J, Gao S, Zhou Q, Zhang M, Wang F, Chen F, Zhou P, Fu Z, Xie H.
    Biomed Pharmacother; 2014 Oct 18; 68(8):935-42. PubMed ID: 25451164
    [Abstract] [Full Text] [Related]

  • 8. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
    Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ.
    Breast Cancer Res; 2009 Oct 18; 11(3):R27. PubMed ID: 19432961
    [Abstract] [Full Text] [Related]

  • 9. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Villegas SL, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, Holms F, Ulmer HU, Fasching PA, Weber KE, Albig C, Heinrichs C, Marmé F, Hartmann A, Hanusch C, Schmitt WD, Huober J, Lederer B, van Mackelenbergh M, Tesch H, Jackisch C, Rezai M, Sinn P, Sinn BV, Hackmann J, Kiechle M, Schneeweiss A, Weichert W, Denkert C, Loibl S.
    Eur J Cancer; 2021 May 18; 148():159-170. PubMed ID: 33743484
    [Abstract] [Full Text] [Related]

  • 10. Identification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy.
    Niwa Y, Yamada S, Sonohara F, Kurimoto K, Hayashi M, Tashiro M, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y.
    J Transl Med; 2019 Jan 03; 17(1):1. PubMed ID: 30602370
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
    Yardley DA, Peacock N, Daniel B, Anz B, Molthrop DC, Shroff SK, Young R, Jankov A, Vander Woude A, Shastry M, Pasek J, DeBusk LM, Hainsworth JD.
    Breast Cancer Res Treat; 2020 Apr 03; 180(3):647-655. PubMed ID: 32060783
    [Abstract] [Full Text] [Related]

  • 12. A 4-microRNA signature predicts lymph node metastasis and prognosis in breast cancer.
    Chen X, Wang YW, Zhu WJ, Li Y, Liu L, Yin G, Gao P.
    Hum Pathol; 2018 Jun 03; 76():122-132. PubMed ID: 29555574
    [Abstract] [Full Text] [Related]

  • 13. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
    Wang YJ, Huang XY, Mo M, Li JW, Jia XQ, Shao ZM, Shen ZZ, Wu J, Liu GY.
    Asian Pac J Cancer Prev; 2015 Jun 03; 16(11):4603-8. PubMed ID: 26107211
    [Abstract] [Full Text] [Related]

  • 14. MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer.
    Pereira CBL, Leal MF, Abdelhay ESFW, Demachki S, Assumpção PP, de Souza MC, Moreira-Nunes CA, Tanaka AMDS, Smith MC, Burbano RR.
    Clin Breast Cancer; 2017 Jun 03; 17(3):188-194. PubMed ID: 28089283
    [Abstract] [Full Text] [Related]

  • 15. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
    Gong C, Tan W, Chen K, You N, Zhu S, Liang G, Xie X, Li Q, Zeng Y, Ouyang N, Li Z, Zeng M, Zhuang S, Lau WY, Liu Q, Yin D, Wang X, Su F, Song E.
    EBioMedicine; 2016 Sep 03; 11():199-209. PubMed ID: 27566954
    [Abstract] [Full Text] [Related]

  • 16. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z, Zhang L, Yu G, Sun Z, Wang T, Tian X, Duan X, Zhang C.
    Cancer Chemother Pharmacol; 2020 Dec 03; 86(6):761-772. PubMed ID: 33068176
    [Abstract] [Full Text] [Related]

  • 17. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M, Toyama T, Takahashi S, Sato S, Yoshimoto N, Endo Y, Asano T, Kobayashi S, Fujii Y, Yamashita H.
    Breast Cancer; 2015 May 03; 22(3):308-16. PubMed ID: 23771556
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Soliman H, Wagner S, Flake DD, Robson M, Schwartzberg L, Sharma P, Magliocco A, Kronenwett R, Lancaster JM, Lanchbury JS, Gutin A, Gradishar W.
    Ann Surg Oncol; 2020 Mar 03; 27(3):765-771. PubMed ID: 31907749
    [Abstract] [Full Text] [Related]

  • 19. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study.
    Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS, Ditzel HJ.
    Mol Oncol; 2014 Jul 03; 8(5):874-83. PubMed ID: 24694649
    [Abstract] [Full Text] [Related]

  • 20. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment.
    Al-Khanbashi M, Caramuta S, Alajmi AM, Al-Haddabi I, Al-Riyami M, Lui WO, Al-Moundhri MS.
    PLoS One; 2016 Jul 03; 11(4):e0152032. PubMed ID: 27064979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.